Brain Monitoring Market

[355 Pages Report] The global brain monitoring market size is estimated to be USD 8.6 billion by 2025 from USD 6.3 billion in 2020, at a CAGR of 6.2%. The brain monitoring market is mainly driven by factors such as the increasing incidence and prevalence of neurological disorders, rising awareness of neurodegenerative diseases, growth in the number of traumatic brain injuries, and increasing applications of brain monitoring in clinical trials. The rising demand for non-invasive and minimally invasive devices, the expanding therapeutic applications of brain monitoring devices, and the growing healthcare market in emerging economies are also expected to provide opportunities for growth for players in the market.

COVID-19 impact on the global Brain Monitoring market

The state of urgency to combat the outbreak has led to a significant increase in the demand for remote monitoring and patient engagement solutions. Most of the hospitals/healthcare facilities are currently trying to expand patient monitoring to homecare settings or other temporary setups with an aim to provide optimal care. COVID-19 has led to a significant surge in the demand for ventilators, and manufacturers are currently focusing their efforts to meet the increasing need for ventilators, including other respiratory devices, in contrast to brain monitoring devices. The pandemic is likely to have an adverse impact on the brain monitoring business particularly due to the focus of hospitals in setting up COVID-19 specific ICUs (intensive care units) along with the temporary suspension of production and manufacturing sites in major affected regions across the globe.

During the first quarter of 2020, the market witnessed an increase in demand for certain products that are correlated to the response to COVID-19, including respiratory, computed tomography (CT), monitoring solutions, x-ray, and anesthesia and point-of-care ultrasound products. However, there was also an observed reduction in demand and delays in procurement in other products and services that are not critical to the COVID-19 response efforts or where procedures like magnetic resonance imaging, nuclear imaging, and electroencephalography, among others could be postponed. Most hospitals have temporarily canceled elective neurology procedures to reduce the risk of exposure to clinicians, staff & patients, and/or to conserve resources to accommodate a surge of COVID-19 patients. COVID-19 is also driving uncertainty in major global markets, as well as leading to additional supply chain and logistics costs. This fluctuation in market growth is expected to last until the next few quarters.

Brain Monitoring Market Dynamics

Driver: Increasing incidence and prevalence of neurological disorders

The global incidence and prevalence of neurological disorders, such as dementia, epilepsy, Parkinson’s disease, Huntington’s disease, headache disorders, multiple sclerosis, neuroinfections, stroke, and cerebral palsy, have increased significantly over the years. Brain disorders, which include a combination of developmental, psychiatric, and neurodegenerative diseases, are a growing cause of morbidity across the globe. This can primarily be attributed to the growing geriatric population (by 2050, more than 20% of the global population is expected to be aged over 65 years). The American Medical Association (AMA) estimates that at least 60% of individuals aged 65 years and above will be living with more than one chronic condition by 2030. Furthermore:

• According to WHO data, in September 2019, around 50 million people are affected by dementia globally, with nearly 10 million new cases registered each year. It is one of the major causes of disability and dependency among older people worldwide.
• According to WHO data, in June 2019, globally, the number of people affected with epilepsy was approximately 50 million; of this, nearly 80% live in low- and middle-income countries.
• The average incidence of epilepsy each year in the US is estimated at 150,000 or 48 for every 100,000 people (Source: Epilepsy Foundation). In the US, around 3.4 million people are affected by epilepsy.
• Approximately 30,000 people in America had Huntington’s disease, and more than 200,000 people were at risk in 2017 (Source: Huntington’s Disease Society of America).
• According to a report published by the Alzheimer’s Association (US), ~476,000 people aged 65 or older developed Alzheimer’s in the US in 2016. An estimated 63,000 new cases in the 65–74 age group, 172,000 new cases in the 75–84 age group, and 241,000 new cases in the 85 or older age group were reported in the US; this is expected to double by 2050.

The rising incidence of these neurological disorders has made it extremely important to monitor brain and neurological functions. Many neurological disorders and conditions are progressive, and their risk increases with age. Additionally, the prevalence of other diseases and conditions, such as sickle-cell diseases and cardiac disorders, is also growing. Cardiac procedures may sometimes affect the normal functioning of the brain, which is another major factor driving the demand for brain monitoring devices.

Restraint: Research High cost of complex brain monitoring procedures and devices

The high cost of brain monitoring surgeries and devices is a major factor restraining the global brain monitoring market, especially in developing countries with poor reimbursement policies. Brain monitoring devices are highly complex, and the procedures involving the use of these devices are generally expensive. For instance, the average cost of a standard EEG is ~USD 200–700; this procedure can cost as high as USD 3,000 for extended monitoring. A dual-channel TCD costs approximately USD 3,000–3,200, and an ICP monitor costs approximately USD 340–500. Likewise, a single MEG system costs roughly USD 2.5–3 million. Due to the high price, healthcare facilities, even in countries that show wide adoption of high-tech medical equipment, find it difficult to procure MEG devices. Additionally, the maintenance cost and other associated indirect expenses increase the total cost of ownership of these devices, thereby limiting their adoption.

Small hospitals and standalone ASCs are also less inclined toward investing in costly and sophisticated technologies due to budgetary constraints; this is more prominent in developing countries. Owing to the high cost of these procedures, coupled with the poor reimbursement scenario, a very limited pool of patients in developing countries can afford neurological treatments. As a result, healthcare facilities are reluctant to invest in new or technologically advanced systems, thus limiting the brain monitoring market.

Opportunity: The increasing demand for non-invasive and minimally invasive devices

Invasive monitoring is a complex, painful, and risky process, as it involves direct intervention with sensitive brain tissue. Doctors and patients, therefore, show a high inclination toward the use of non-invasive or minimally invasive brain monitoring devices. Owing to their advantages, there has been a rapid increase in the demand for non-invasive ICP monitors, TCD devices, tympanic membrane displacement procedures, optic nerve sheath diameter, CT scan/MRI, and fundoscopy, which are reliable alternatives to invasive techniques, thus compelling players in this market to develop and commercialize such products.

• In March 2019, Masimo (US) received CE Mark approval for its next-generation SedLine brain function monitor for pediatric patients aged between one and 18 years of age; this product assesses the brain function while the patient is under anesthesia.
• In March 2018, Nihon Kohden (Japan) launched aireeg WEE-1200, a wireless EEG system that provides real-time data during long-term epilepsy monitoring, intensive care, and routine EEG.
• In March 2016, HeadSense Medical Ltd. (Israel) developed HS-1000, a novel non-invasive device for ICP monitoring.
• In October 2015, Vittamed Corporation (US) received USD 10 million in venture funding from Xeraya Capital Labuan Ltd. (Malaysia) for the commercialization of its novel non-invasive ICP monitoring system.
• In August 2015, Cerebrotech Medical Systems, Inc. (US) received the CE Mark for its non-invasive intracranial fluids monitor, thus allowing it to commercialize the product in the EU.

Several government initiatives are focused on the development of novel and innovative devices, such as the BRAIN initiative launched in the US in April 2013, for encouraging R&D related to the functioning of the brain. Advanced Research Projects Activity (IARPA) joined the BRAIN initiative for the development of non-invasive neural intervention devices for optimizing reasoning and problem-solving.

By product, the devices segment accounted for the largest share of the Brain Monitoring market in 2019.

By product, the global brain monitoring market is categorized into devices and accessories. The devices segment held the largest share of the brain monitoring market in 2019. This is mainly due to the rising incidence of neurological, neurodegenerative, psychotic, and sleep disorders, the need for early diagnosis, the availability of innovative portable and wearable home-based monitoring devices, and increasing patient awareness.

By medical condition, the traumatic brain injury segment accounted for the largest share of the brain monitoring market in 2019.

Based on disease, the brain monitoring market is segmented into traumatic brain injury (TBI), stroke, dementia, headache disorders, sleep disorders, Parkinson’s disease, epilepsy, Huntington’s disease, and other diseases. The Brain Monitoring market has been segmented into regenerative medicine and stem cell research, cancer & cell-based research, and others. Traumatic brain injury (TBI) holds the largest share of the brain monitoring market by a medical condition. A major factor responsible for the large share of this market segment is the growing incidence of TBIs across the globe, leading to high demand for the management of these cases, thus requiring the intensive use of brain monitoring devices.

By end user type, the hospital segment accounted for the largest share of the brain monitoring market in 2019.

Based on end-users, the global brain monitoring devices market is segmented into hospitals, neurology centers, diagnostic centers, ASCs & clinics, and other end users. The hospital segment held the largest share of the global brain monitoring market in 2019. Brain monitoring is a complex process, requiring expensive and advanced devices and equipment that are mainly found in hospitals. Hospitals also see a considerably larger inflow of patients as compared to small clinics and other end users. Additionally, brain monitoring devices pose a considerable burden in terms of maintenance expenses on healthcare facilities; hospitals, more than other end-users, can bear such costs. Hence, brain monitoring devices are mostly used in hospitals, which consequently account for the largest share of this market segment.

North America accounted for the largest share of the global brain monitoring market in 2019.

The brain monitoring market, by region, is segmented into North America, Europe, APAC, and the RoW. North America accounted for the largest share of the brain monitoring market in 2018. This can be attributed to the growing incidence of neurological diseases, a growing number of clinical trials of brain monitoring products, and the availability of medical reimbursement in the US.

Key Market Players

The global Brain Monitoring market is dominated by a few globally established players such as Natus Medical, Inc. (US), Nihon Kohden Corporation (Japan), Philips Healthcare (Netherlands), GE Healthcare (US), Siemens Healthineers (Germany), Compumedics, Ltd. (Australia), Medtronic (Ireland), CAS Medical Systems, Inc. (US), Drägerwerk AG & Co. KGaA (Germany), Advanced Brain Monitoring (US), Masimo Corporation (US), Spiegelberg GmbH & Co. KG (Germany), Cadwell Industries (US), NeuroWave Systems, Inc. (US), Nonin Medical, Inc. (US), Integra LifeSciences Corporation (US), Neurosoft (Russia), and Rimed (US)

Scope of the report

The study categorizes the Brain Monitoring market into the following segments and subsegments:

By Product

• Devices
• By Type
  • Magnetic Resonance Imaging (MRI) Scanners
  • Computerized Tomography (CT) Scanners
  • Electroencephalograph (EEG) Devices
  • Positron Emission Tomography (PET) Scanners
  • Sleep Monitoring Devices
  • Cerebral Oximeters
  • Electromyography (EMG) Devices
  • Intracranial Pressure (ICP) Monitors
  • Magnetoencephalography (MEG) Devices
  • Transcranial Doppler (TCD) Devices
• By Procedure
  • Devices for Invasive Procedures
  • Devices for Non-invasive Procedures
• Accessories
  • By Type
    • Electrodes
      • Wet Electrodes
      • Dry Electrodes
      • Needle Electrodes
    • Sensors
    • Pastes & Gels
    • Caps
    • Cables
    • Batteries
    • Other Accessories
  • By Usability
    • Disposable
    • Reusable

By Medical Condition

• Traumatic Brain Injury (TBI)
• Stroke
• Dementia
• Headache Disorders
• Sleep Disorders
• Parkinson’s Disease
• Epilepsy
• Huntington's Disease
• Other Medical Conditions 

By End User

• Hospitals
• Neurology Centers
• Ambulatory Surgery Centers (ASCs) & Clinics
• Diagnostic Centers
• Other End Users

By Region

• North America
  • US
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Rest of Asia Pacific
• Rest of the World
  • Latin America
  • The Middle East and Africa

Recent Developments

• In 2018, GE Healthcare launched its SIGNA Premier 3.0T magnetic resonance imaging (MRI) system in Canada.
• In 2018, Philips collaborated with Samsung Electronics to connect Samsung’s ARTIK Smart IoT Platform to Philips’ HealthSuite Digital Platform. This addressed the growing need for connected health platforms that can safely access, share, and analyze information, helping health systems and providers achieve their goal of delivering better care to consumers.
• In 2017, Natus acquired the global Camino ICP monitoring product line, including its San Diego manufacturing facility, from Integra. The sale also included the US rights to Integra's fixed-pressure shunts, as well as US rights to Codman's DURAFORM dural graft implants, standard EVD catheters, and CSF collection systems.
• In 2017, Philips acquired Electrical Geodesics to expand its existing portfolio of imaging technologies and advanced informatics for neurological applications.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst